Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Norepinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.74 |
| ▸ | ADRB2 known ✓ | P07550 | 4/20 | 0.74 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.74 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.74 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.74 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.74 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.74 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.74 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | RECQL | P46063 | 6/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.74 |
| ▸ | BLM | P54132 | 6/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.74 |
| ▸ | DRD2 | P14416 | 4/20 | 0.74 |
| ▸ | DRD1 | P21728 | 4/20 | 0.74 |
| ▸ | APEX1 | P27695 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epinephrine SCHEMBL8465140 | 0.89 | TDP1 (0.67) | MAPTRECQLTDP1BLMKDM4E | |
| Isoproterenol SCHEMBL28086470 | 0.87 | MAPT (0.68) | MAPTRECQLTDP1BLMKDM4E | |
| L-Norepinephrine SCHEMBL2610 | 0.86 | TDP1 (1.00) | MAPTRECQLTDP1BLMKDM4E | |
| L-Norepinephrine SCHEMBL3489077 | 0.86 | TDP1 (1.00) | MAPTRECQLTDP1BLMKDM4E | |
| L-Norepinephrine SCHEMBL29371849 | 0.86 | TDP1 (1.00) | MAPTRECQLTDP1BLMKDM4E | |
| Norepinephrine SCHEMBL2609 | 0.86 | TDP1 (1.00) | MAPTRECQLTDP1BLMKDM4E | |
| L-Norepinephrine SCHEMBL29460319 | 0.86 | TDP1 (1.00) | MAPTRECQLTDP1BLMKDM4E | |
| Norepinephrine SCHEMBL2429869 | 0.86 | TDP1 (1.00) | MAPTRECQLTDP1BLMKDM4E | |
| Norepinephrine SCHEMBL29399946 | 0.86 | TDP1 (1.00) | MAPTRECQLTDP1BLMKDM4E | |
| L-Norepinephrine SCHEMBL317206 | 0.84 | BLM (0.96) | MAPTRECQLTDP1BLMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015331-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR MULTIPLE SCLEROSIS | GENENTECH, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| WO-2023233357-A1 | SUBCUTANEOUS ADMINISTRATION OF ONFASPRODIL AND DOSING METHODS FOR USE IN THE TREATMENT OF DEPRESSION DISORDERS | NOVARTIS AG (CH) | 2023-12-07 | — | — | WO | claimed |
| CN-116782865-A | Atomic layer deposition coated pharmaceutical packages, improved syringes and vials, e.g., for lyophilization/cold chain drugs/vaccines | SIO2医药产品公司 | 2023-09-19 | — | — | CN | claimed |
| US-20230285387-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | claimed |
| WO-2023164386-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023164387-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023164385-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023163879-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023159035-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| WO-2023158668-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| US-20080058345-A1 | Combination Therapy with Mecamylamine for the Treatment of Mood Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | claimed |
| EP-1874353-A1 | GLUTAMATE MODULATING AGENTS IN THE TREATMENT OF MENTAL DISORDERS | YALE UNIVERSITY (US) | 2008-01-09 | — | — | EP | claimed |
| US-20080003275-A1 | Treatment of Premature Ejaculation | WORLDWIDE PE PATENT HOLDCO PTY LTD. (US) | 2008-01-03 | — | — | US | claimed |
| US-20060270647-A1 | Glutamate agents in the treatment of mental disorders | YALE UNIVERSITY (US) | 2006-11-30 | — | — | US | claimed |
| CN-1852704-A | Treatment of premature ejaculation | WORLDWIDE PE PATENT HOLDCO PTY (AU) | 2006-10-25 | — | — | CN | claimed |
| WO-2006108055-A1 | GLUTAMATE MODULATING AGENTS IN THE TREATMENT OF MENTAL DISORDERS | YALE UNIVERSITY (US) | 2006-10-12 | — | — | WO | claimed |
| US-20060167068-A1 | Method of treating self-injurious behavior with glutamate modulating agents | FEUERSTEIN SETH | 2006-07-27 | — | — | US | claimed |
| EP-1648430-A1 | TREATMENT OF PREMATURE EJACULATION | Worldwide PE Patent Holdco Pty Ltd (AU) | 2006-04-26 | — | — | EP | claimed |
| WO-2005067909-A1 | COMBINATION THERAPY WITH MECAMYLAMINE FOR THE TREATMENT OF MOOD DISORDERS | YALE UNIVERSITY (US) | 2005-07-28 | — | — | WO | claimed |
| WO-2005004855-A1 | TREATMENT OF PREMATURE EJACULATION | WORLDWIDE PE PATENT HOLDCO PTY LTD (AU) | 2005-01-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285387-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | MAOB, DBH, OPRL1 | ADRA2A 104/4885ADRB2 34/4885ADRA1D 73/4885 |
| US-20060167068-A1 | Method of treating self-injurious behavior with glutamate modulating agents | GRM6, GRM4, GRM5 | ADRA2A 1270/4885ADRB2 2214/4885ADRA1D 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.